Stockreport

Relypsa Announces Phase 4 Study Shows Veltassa® Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia

RELYPSA  (RLYP) 
US:NASDAQ Investor Relations: relypsa.com/newsroom/investors
PDF REDWOOD CITY, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the Phase 4 TOURMALINE study, wh [Read more]